• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    6/20/23 9:13:29 AM ET
    $BFRI
    $BJDX
    $CANO
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BFRI alert in real time by email

    Gainers

    • Evelo Biosciences (NASDAQ:EVLO) stock increased by 60.7% to $0.19 during Tuesday's pre-market session. The company's market cap stands at $21.6 million.
    • DICE Therapeutics (NASDAQ:DICE) shares moved upwards by 38.07% to $46.74. The market value of their outstanding shares is at $2.2 billion.
    • Nuwellis (NASDAQ:NUWE) stock moved upwards by 34.81% to $3.95. The company's market cap stands at $4.7 million.
    • Biofrontera (NASDAQ:BFRI) shares increased by 29.54% to $0.57. The company's market cap stands at $15.2 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares increased by 25.11% to $2.74. The market value of their outstanding shares is at $23.0 million.
    • Cano Health (NYSE:CANO) stock increased by 20.79% to $1.51. The market value of their outstanding shares is at $421.1 million.

    Losers

    • Surgalign Holdings (NASDAQ:SRGA) shares declined by 62.3% to $0.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.2 million.
    • Infinity Pharmaceuticals (NASDAQ:INFI) stock decreased by 14.71% to $0.2. The company's market cap stands at $18.2 million.
    • Xenetic Biosciences (NASDAQ:XBIO) stock fell 10.03% to $3.05. The market value of their outstanding shares is at $4.6 million.
    • MAIA Biotechnology (AMEX:MAIA) shares decreased by 9.88% to $2.1. The market value of their outstanding shares is at $28.6 million.
    • Nexalin Technology (NASDAQ:NXL) stock fell 9.4% to $0.83. The market value of their outstanding shares is at $6.0 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock declined by 8.29% to $0.2. The market value of their outstanding shares is at $4.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRI
    $BJDX
    $CANO
    $DICE

    CompanyDatePrice TargetRatingAnalyst
    Nuwellis Inc.
    $NUWE
    7/29/2024$17.00Buy
    ROTH MKM
    Cano Health Inc.
    $CANO
    8/11/2023Buy → Hold
    Jefferies
    Cano Health Inc.
    $CANO
    8/11/2023$4.00 → $0.80Buy → Neutral
    Citigroup
    DICE Therapeutics Inc.
    $DICE
    5/24/2023$38.00Equal Weight
    Wells Fargo
    DICE Therapeutics Inc.
    $DICE
    5/22/2023$71.00Buy
    Canaccord Genuity
    DICE Therapeutics Inc.
    $DICE
    3/31/2023$56.00Buy
    Needham
    DICE Therapeutics Inc.
    $DICE
    3/1/2023Outperform
    TD Cowen
    DICE Therapeutics Inc.
    $DICE
    3/1/2023Outperform
    Cowen
    More analyst ratings

    $BFRI
    $BJDX
    $CANO
    $DICE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/10/26 4:02:58 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    3/9/26 9:20:28 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Bluejay Diagnostics Inc.

    10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 4:02:15 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Weber Kevin Daniel

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:33:07 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:31:43 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Leffler Eugene Frederick converted options into 87,500 shares, increasing direct ownership by 100% to 175,000 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:30:26 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Nuwellis with a new price target

    ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

    7/29/24 7:42:07 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cano Health downgraded by Jefferies

    Jefferies downgraded Cano Health from Buy to Hold

    8/11/23 10:23:10 AM ET
    $CANO
    Medical/Nursing Services
    Health Care

    Cano Health downgraded by Citigroup with a new price target

    Citigroup downgraded Cano Health from Buy to Neutral and set a new price target of $0.80 from $4.00 previously

    8/11/23 7:12:10 AM ET
    $CANO
    Medical/Nursing Services
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Gross Harrison R. bought $2,400 worth of shares (1,500 units at $1.60), increasing direct ownership by 14% to 12,233 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/12/26 5:00:39 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BFRI
    $BJDX
    $CANO
    $DICE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 3:54:03 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care